Suboptimal response or treatment failure to standard-dose imatinib are relevant problems in chronic-phase chronic myeloid leukemia patients. Insufficient adherence is one of the main causes of ...
Imatinib mesylate in chronic myeloid leukemia (CML): A single institution experience of 174 patients
VAD (vincristine, doxorubicin and high-dose dexamethasone) administered as intravenous bolus (IVB) injection as first-line treatment in multiple myeloma (MM) Background: Imatinib mesylate is a novel ...
Lead CML researcher discusses the evolution of a groundbreaking treatment and its effect on patient survival. When imatinib (Gleevec; Novartis), the first-ever tyrosine kinase inhibitor, made its ...
There has been much speculation on the potential use of kinase inhibitors for the treatment of autoimmune rheumatic diseases. Investigations of small-molecule inhibitors of p38 mitogen-activated ...
The FDA has cleared Inhibikase Therapeutics Inc.'s IND application for IkT-001Pro for the treatment of chronic myelogenous leukemia (CML). IkT-001Pro is a prodrug formulation of imatinib mesylate and ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved IMKELDI (imatinib) oral solution, the first ...
Imatinib (Imkeldi) is the first oral liquid TKI approved for multiple cancers, enhancing treatment accessibility and dosing precision. The drug is effective as a first-line treatment, especially in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback